SwePub
Sök i SwePub databas

  form:Ext_t

Träfflista för sökning "WFRF:(Henriksson Roger) "

form:Search_simp_t: WFRF:(Henriksson Roger)

  • navigation:Result_t 1-10 navigation:of_t 291
hitlist:Modify_result_t
   
hitlist:Enumeration_thitlist:Reference_thitlist:Reference_picture_thitlist:Find_Mark_t
1.
  • Ljuslinder, Ingrid, 1968-, et al. (creator_code:aut_t)
  • ErbB 1-4 expression alterations in primary colorectal cancers and their corresponding metastases
  • 2009
  • record:In_t: Anticancer Research. - 0250-7005 .- 1791-7530. ; 29:5, s. 1489-1494
  • swepub:Mat_article_t (swepub:level_refereed_t)abstract
    • BACKGROUND: EGFR (epidermal growth factor receptor) targeted therapies are important new tools in colorectal cancer treatment. EGFR analysis of the primary tumour was previously recommended to identify patients who will benefit from the EGFR targeted therapy. Previous studies have displayed diverging results regarding the expression of EGFR in the primary tumour compared to the metastases. The present study was performed to investigate whether EGFR and ErbB2-4 expression differed between 64 primary tumours and their corresponding metastases. PATIENTS AND METHODS: EGFR and ErbB2-4 expression were analysed in the primary tumour and in the corresponding metastases using immunohistochemistry (IHC). RESULTS: In 49/64 samples (76%), the primary tumours were EGFR positive; in 33% (16/49) of EGFR positive samples, the tumours lost the EGFR expression in the metastasis compared to the primary tumour. From the primary tumours, 15/64 (23%) were negative and 5 of these (33%) developed EGFR expression in the metastasis. ErbB2, ErbB3, and ErbB4 expression was evident in 54%, 67%, and 81%, respectively. There was no significant difference between ErbB2, ErbB3, and ErbB4 expression in primary tumours and metastases. The co-expression of the ErbB family members was also analysed, with a significant increase of ErbB3/ErbB4 co-expression in late stage tumours. CONCLUSION: The EGFR expression was lost in 33% of metastasising primary colorectal cancer tumours, a finding that agrees with at least one previous study. Thus, the present results clearly implicate the need for EGFR analysis of both the primary tumour and metastases to accurately determine EGFR status when considering the use of EGFR targeted therapies.
  •  
2.
  • Ljuslinder, Ingrid, 1968-, et al. (creator_code:aut_t)
  • LRIG1 expression in colorectal cancer
  • 2007
  • record:In_t: Acta Oncologica. - : Informa UK Limited. - 0284-186X .- 1651-226X. ; 46:8, s. 1118-1122
  • swepub:Mat_article_t (swepub:level_refereed_t)
  •  
3.
  • Malmström, Annika, et al. (creator_code:aut_t)
  • Temozolomide versus standard 6-week radiotherapy versus hypofractionated radiotherapy in patients older than 60 years with glioblastoma: the Nordic randomised, phase 3 trial
  • 2012
  • record:In_t: The Lancet Oncology. - : Elsevier. - 1470-2045 .- 1474-5488. ; 13:9, s. 916-926
  • swepub:Mat_article_t (swepub:level_refereed_t)abstract
    • Background Most patients with glioblastoma are older than 60 years, but treatment guidelines are based on trials in patients aged only up to 70 years. We did a randomised trial to assess the optimum palliative treatment in patients aged 60 years and older with glioblastoma. less thanbrgreater than less thanbrgreater thanMethods Patients with newly diagnosed glioblastoma were recruited from Austria, Denmark, France, Norway, Sweden, Switzerland, and Turkey. They were assigned by a computer-generated randomisation schedule, stratified by centre, to receive temozolomide (200 mg/m(2) on days 1-5 of every 28 days for up to six cycles), hypofractionated radiotherapy (34.0 Gy administered in 3.4 Gy fractions over 2 weeks), or standard radiotherapy (60.0 Gy administered in 2.0 Gy fractions over 6 weeks). Patients and study staff were aware of treatment assignment. The primary endpoint was overall survival. Analyses were done by intention to treat. This trial is registered, number ISRCTN81470623. less thanbrgreater than less thanbrgreater thanFindings 342 patients were enrolled, of whom 291 were randomised across three treatment groups (temozolomide n=93, hypofractionated radiotherapy n=98, standard radiotherapy n=100) and 51 of whom were randomised across only two groups (temozolomide n=26, hypofractionated radiotherapy n=25). In the three-group randomisation, in comparison with standard radiotherapy, median overall survival was significantly longer with temozolomide (8.3 months [95% CI 7.1-9.5; n=93] vs 6.0 months [95% CI 5.1-6.8; n=100], hazard ratio [HR] 0.70; 95% CI 0.52-0.93, p=0.01), but not with hypofractionated radiotherapy (7.5 months [6.5-8.6; n=98], HR 0.85 [0.64-1.12], p=0.24). For all patients who received temozolomide or hypofractionated radiotherapy (n=242) overall survival was similar (8.4 months [7.3-9.4; n=119] vs 7.4 months [6.4-8.4; n=123]; HR 0.82, 95% CI 0.63-1.06; p=0.12). For age older than 70 years, survival was better with temozolomide and with hypofractionated radiotherapy than with standard radiotherapy (HR for temozolomide vs standard radiotherapy 0.35 [0.21-0.56], pandlt;0.0001; HR for hypofractionated vs standard radiotherapy 0.59 [95% CI 0.37-0.93], p=0.02). Patients treated with temozolomide who had tumour MGMT promoter methylation had significantly longer survival than those without MGMT promoter methylation (9.7 months [95% CI 8.0-11.4] vs 6.8 months [5.9-7.7]; HR 0.56 [95% CI 0.34-0.93], p=0.02), but no difference was noted between those with methylated and unmethylated MGMT promoter treated with radiotherapy (HR 0.97 [95% CI 0.69-1.38]; p=0.81). As expected, the most common grade 3-4 adverse events in the temozolomide group were neutropenia (n=12) and thrombocytopenia (n=18). Grade 3-5 infections in all randomisation groups were reported in 18 patients. Two patients had fatal infections (one in the temozolomide group and one in the standard radiotherapy group) and one in the temozolomide group with grade 2 thrombocytopenia died from complications after surgery for a gastrointestinal bleed. less thanbrgreater than less thanbrgreater thanInterpretation Standard radiotherapy was associated with poor outcomes, especially in patients older than 70 years. Both temozolomide and hypofractionated radiotherapy should be considered as standard treatment options in elderly patients with glioblastoma. MGMT promoter methylation status might be a useful predictive marker for benefit from temozolomide.
  •  
4.
  •  
5.
  • Weller, Michael, et al. (creator_code:aut_t)
  • EANO guideline for the diagnosis and treatment of anaplastic gliomas and glioblastoma
  • 2014
  • record:In_t: The Lancet Oncology. - 1470-2045 .- 1474-5488. ; 15:9, s. E395-E403
  • swepub:Mat_researchreview_t (swepub:level_refereed_t)abstract
    • This guideline provides recommendations for diagnostic and therapeutic procedures for patients with malignant gliomas. We differentiate evidence-based standards from reasonable options or non-evidence-based measures that should no longer be considered. The recommendations herein should provide a framework and assurance for the choice of diagnostic procedures and therapeutic measures and aim to reduce complications from unnecessary treatment and cost. The guideline contributes to a critical appreciation of concurrent drugs with a focus on the controlled use of anticonvulsants and steroids. It should serve as a guideline for all professionals involved in the diagnostics and care of glioma patients and also as a source of knowledge for insurance companies and other institutions involved in the cost regulation of cancer care in Europe. Implementation of the recommendations summarised here will need interdisciplinary structures of care for patients with brain tumours and structured processes of diagnostic and therapeutic procedures.
  •  
6.
  •  
7.
  •  
8.
  • Alexandra, Wide, et al. (creator_code:aut_t)
  • Fertility-related information received by young women and men with cancer : a population-based survey
  • 2021
  • record:In_t: Acta Oncologica. - : Taylor & Francis. - 0284-186X .- 1651-226X. ; 60:8, s. 976-983
  • swepub:Mat_article_t (swepub:level_refereed_t)abstract
    • Background: Infertility is a well-known sequela of cancer treatment. Despite guidelines recommending early discussions about risk of fertility impairment and fertility preservation options, not all patients of reproductive age receive such information.Aims: This study aimed to investigate young adult cancer patients' receipt of fertility-related information and use of fertility preservation, and to identify sociodemographic and clinical factors associated with receipt of information.Materials and methods: A population-based cross-sectional survey study was conducted with 1010 young adults with cancer in Sweden (response rate 67%). The inclusion criteria were: a previous diagnosis of breast cancer, cervical cancer, ovarian cancer, brain tumor, lymphoma or testicular cancer between 2016 and 2017, at an age between 18 and 39 years. Data were analyzed using logistic regression models.Results: A majority of men (81%) and women (78%) reported having received information about the potential impact of cancer/treatment on their fertility. A higher percentage of men than women reported being informed about fertility preservation (84% men vs. 40% women, p < .001) and using gamete or gonadal cryopreservation (71% men vs. 15% women, p < .001). Patients with brain tumors and patients without a pretreatment desire for children were less likely to report being informed about potential impact on their fertility and about fertility preservation. In addition, being born outside Sweden was negatively associated with reported receipt of information about impact of cancer treatment on fertility. Among women, older age (>35 years), non-heterosexuality and being a parent were additional factors negatively associated with reported receipt of information about fertility preservation.Conclusion: There is room for improvement in the equal provision of information about fertility issues to young adult cancer patients.
  •  
9.
  •  
10.
  • Andersson, Britta, 1979- (creator_code:aut_t)
  • Manipulation of potassium ion fluxes to induce apoptosis in lung cancer cells
  • 2007
  • swepub:Mat_doctoralthesis_t (swepub:level_scientificother_t)abstract
    • Apoptosis is a special form of cell death that if non-functional may lead to diseases such as cancer. A reduction of the intracellular potassium ion (K+) content is necessary for activating enzymes important for the execution of apoptosis. Pharmacological modulation of K+ fluxes to reduce intracellular K+ in cancer cells might therefore force the cells into apoptosis and decrease tumour cell mass. Human malignant pleural mesothelioma (MPM) is a form of cancer often caused by asbestos exposure. Although asbestos has been banned in the Western World, the incidence of MPM is expected to increase. Cisplatin is the first-line chemotherapy for MPM, but acquired resistance to the drug is a clinical problem. This thesis is mainly based on work with the human malignant pleural mesothelioma cell line (P31 wt) and a cisplatin-resistant sub-line (P31 res). The aim was to first characterize K+ fluxes in P31 wt and P31 res cells, and then manipulate them in order to reduce intracellular K+ and induce apoptosis with K+ manipulation alone or in combination with cisplatin. Characterization of K+ fluxes in P31 wt cells showed that: 1) ouabain, a digitalis-like drug, and specific blocker of the Na+, K+, ATPase pump, effectively inhibited K+ uptake, 2) bumetanide, a diuretic, and an inhibitor of the Na+, K+, 2Cl-¬-cotransporter, had a transient effect on K+ uptake, and 3) the antifungal drug amphotericin B stimulated K+ efflux. In order to determine intracellular K+ content, the potassium-binding fluorescent probe PBFI-AM was used in a 96-well plate assay. After a 3-h incubation with ouabain, with or without bumetanide, combined with amphotericin B, the intracellular K+ content was reduced in P31 wt cells but not in P31 res cells. Ouabain induced apoptosis in both P31 wt and P31 res cells. P31 res cells were sensitized to cisplatin by ouabain, since 10 mg/L cisplatin in combination with ouabain induced about the same percentage of apoptotic cells as 40 mg/L cisplatin. Apoptosis was executed via caspase-3 activation in both P31 wt and P31 res cells. Amphotericin B enhanced ouabain-induced apoptosis in P31 wt cells via caspase-9 activation, with increased caspase-3 activation and DNA fragmentation as consequences. Ouabain-induced apoptosis in P31 res cells was executed via increased expression of pro-apoptotic Bak. The combination of cisplatin with ouabain and amphotericin B was stressful to both P31 wt and P31 res cells, since SAPK/JNK a known factor in stress-induced apoptosis was activated. In conclusion, K+ flux manipulation with clinical used drugs can induce apoptosis per se and also enhance cisplatin-induced apoptosis in P31 wt and P31 res cells.
  •  
Skapa referenser, mejla, bekava och länka
  • navigation:Result_t 1-10 navigation:of_t 291
swepub:Mat_t
swepub:mat_article_t (237)
swepub:mat_doctoralthesis_t (24)
swepub:mat_publicationother_t (13)
swepub:mat_researchreview_t (9)
swepub:mat_conferencepaper_t (5)
swepub:mat_chapter_t (3)
deldatabas:search_more_t
deldatabas:search_less_t
swepub:Level_t
swepub:level_refereed_t (226)
swepub:level_scientificother_t (62)
swepub:level_popularscientific_t (3)
swepub:Hitlist_author_t
Henriksson, Roger (262)
Hedman, Håkan (55)
Andersson, Ulrika (26)
Bergenheim, A Tommy (22)
Johansen, Christoffe ... (20)
Saran, Frank (19)
deldatabas:search_more_t
Malmer, Beatrice (19)
Bergqvist, Michael (17)
Feychting, Maria (17)
Johansson, Mikael (17)
Ahlbom, Anders (16)
Asklund, Thomas (16)
Lenner, Per (15)
Melin, Beatrice S. (15)
Grankvist, Kjell (14)
Hemminki, Kari (14)
Johansson, Robert (13)
Brännström, Thomas (13)
Försti, Asta (13)
Henriksson, Roger, P ... (13)
Ekman, Simon (12)
Nilsson, Jonas (11)
Malmström, Annika (11)
Hallmans, Göran (10)
Swerdlow, Anthony (10)
Melin, Beatrice (10)
Tavelin, Björn (10)
Lönn, Stefan (10)
Sandström, Maria (10)
Chanock, Stephen J (9)
Yeager, Meredith (9)
Jakola, Asgeir Store (9)
Wibom, Carl (9)
Muir, Kenneth (8)
Gapstur, Susan M (8)
Stevens, Victoria L (8)
Giles, Graham G (8)
White, Emily (8)
Peters, Ulrike (8)
Severi, Gianluca (8)
Chatterjee, Nilanjan (8)
Gaziano, J Michael (8)
Zeleniuch-Jacquotte, ... (8)
Hartge, Patricia (8)
Behnam Motlagh, Parv ... (8)
Auvinen, Anssi (8)
Kiuru, Anne (8)
Guo, Dongsheng (8)
Smits, Anja (8)
Rothman, Nathaniel (8)
deldatabas:search_less_t
swepub:Hitlist_uni_t
swepub_uni:umu_t (265)
swepub_uni:ki_t (43)
swepub_uni:uu_t (40)
swepub_uni:lu_t (26)
swepub_uni:liu_t (17)
swepub_uni:gu_t (10)
deldatabas:search_more_t
swepub_uni:ltu_t (2)
swepub_uni:oru_t (1)
deldatabas:search_less_t
hitlist:Language_t
language:Eng_t (279)
language:Swe_t (9)
language:Und_t (3)
hitlist:HSV_t
hsv:Cat_3_t (185)
hsv:Cat_1_t (9)
hsv:Cat_5_t (4)
hsv:Cat_2_t (1)
hsv:Cat_4_t (1)

hitlist:Year_t

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt tools:Close_t

tools:Permalink_label_t